Human papillomavirus (HPV) vaccine utilization among adults (18-29  years), BRFSS 2015.

Human papillomavirus (HPV) vaccine utilization among adults (18-29 years), BRFSS 2015.
Vaccine. 2020 Jun 18;:
Authors: Wiener RC, Findley PA, Shen C, Dwibedi N, Sambamoorthi U
Abstract
Human papillomavirus (HPV) vaccination acceptance is hampered by fears and conflicting attitudes about the need for and safety of vaccine. There are also ethical dilemmas associated with vaccinating adolescents for a sexually transmitted disease despite future cancer risk. The purpose of this research was to determine HPV vaccination acceptance/hesitancy among young adults. Behavioral Risk Factor Surveillance System 2015 data were used. During 2015, 83.1% of adults ages 25-29 years did not receive any HPV vaccination; the UOR was 3.47; 95% CI = 2.11, 5.70) compared to adults 18-24 years. There is a need to accelerate public health messaging/campaigns to increase HPV vaccination rates.
PMID: 32565345 [PubMed - as supplied by publisher]

Source: Vaccine - June 17, 2020 Category: Allergy & Immunology Authors: Wiener RC, Findley PA, Shen C, Dwibedi N, Sambamoorthi U Tags: Vaccine Source Type: research